Stratos Wealth Partners LTD. Has $3.74 Million Position in Gilead Sciences, Inc. (GILD)
Stratos Wealth Partners LTD. lowered its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 40.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 46,172 shares of the biopharmaceutical company’s stock after selling 31,280 shares during the quarter. Stratos Wealth Partners LTD.’s holdings in Gilead Sciences were worth $3,741,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Hanson & Doremus Investment Management increased its stake in Gilead Sciences by 806.5% in the third quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock valued at $147,000 after acquiring an additional 1,613 shares during the period. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Gilead Sciences in the second quarter valued at about $147,000. Harel Insurance Investments & Financial Services Ltd. increased its stake in Gilead Sciences by 29.3% in the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,120 shares of the biopharmaceutical company’s stock valued at $150,000 after acquiring an additional 480 shares during the period. Rowland & Co. Investment Counsel ADV bought a new stake in Gilead Sciences in the second quarter valued at about $153,000. Finally, Capstone Investment Advisors Netherlands B.V. bought a new stake in Gilead Sciences in the second quarter valued at about $172,000. 75.95% of the stock is currently owned by institutional investors and hedge funds.
In other news, insider John F. Milligan sold 220,000 shares of the company’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $72.88, for a total transaction of $16,033,600.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $75.13, for a total transaction of $5,509,508.29. Following the transaction, the insider now owns 3,070,099 shares in the company, valued at $230,656,537.87. The disclosure for this sale can be found here. Insiders have sold 461,666 shares of company stock worth $34,072,567 over the last quarter. 1.30% of the stock is owned by company insiders.
Gilead Sciences, Inc. (NASDAQ:GILD) opened at $79.02 on Tuesday. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $86.27. The stock has a market cap of $103,190.00, a P/E ratio of 8.99, a PEG ratio of -1.68 and a beta of 1.13. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The company had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. During the same period in the prior year, the business earned $2.75 earnings per share. Gilead Sciences’s quarterly revenue was down 13.2% on a year-over-year basis. research analysts anticipate that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Thursday, December 28th. Stockholders of record on Friday, December 15th were given a dividend of $0.52 per share. The ex-dividend date was Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.63%. Gilead Sciences’s payout ratio is 23.66%.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.